Celldex Therapeutics
Tracked across 2 events · 18 articles · First seen Mar 01, 2026 · Last active Apr 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Celldex Therapeutics presented positive Phase 2 data for barzolvolimab, demonstrating its efficacy in treating Cold Urticaria and Symptomatic Dermographism. This positive data supports the drug's potential as a best-in-class treatment and strengthens Celldex Therapeutics' position in the immunology market. The company is also initiating a global Phase 3 trial for barzolvolimab.
Mar 01, 2026 · 7 articles
Business
Celldex Therapeutics successfully completed a public offering of its common stock, raising approximately $345 million. This capital infusion is intended to fund commercial readiness for barzolvolimab, ongoing clinical development, and general corporate purposes, which is a positive for the company's future operations and growth.
Apr 01, 2026 · 11 articles
Diane Young
Senior Vice President and Chief Medical Officer
↔
Celldex Therapeutics
Diane Young holds a leadership position at Celldex Therapeutics.
NEWSDESK
Track Celldex Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard